The Valve Wire sealThe Valve Wire
October 19, 2026E. Nolan Beckett, MD · Editor
LIVE · 11:57 ET · OCT 19, 2026
EW ▲ MDT ▼ ABT ▼ BSX ▲
Aortic Valve (TAVR/TAVI)Monday, October 19, 2026

Unmasking Brugada Syndrome With Oral Propafenone in a Resource-Limited Setting: A Case Report.

1 min read·By E. Nolan Beckett, MD·Source: Cureus
From The Valve Wire

Access-site strategy is the next place TAVR outcomes get refined, and a 600-patient trial is now locked.

The Freiburg-Bad Krozingen group's radial versus femoral secondary access study moved to active, not recruiting.

Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract

Brugada syndrome (BrS) is a cardiac channelopathy predisposing patients to malignant ventricular arrhythmias and sudden cardiac death (SCD) in the absence of structural heart disease. The diagnosis requires documentation of a type 1 Brugada electrocardiographic pattern, which can be unmasked using sodium channel-blocking agents in symptomatic patients presenting with non-diagnostic baseline patterns. We report a case of a 24-year-old male patient with a history of unexplained syncope who exhibited a non-diagnostic type 2 Brugada pattern on a baseline electrocardiogram (ECG). Due to the local unavailability of standard intravenous antiarrhythmics, a pharmacological provocation test was conducted using a single 600 mg oral dose of propafenone. Under continuous cardiac monitoring, the patient safely developed a diagnostic type 1 "coved" electrocardiographic pattern starting at the third hour, confirming the diagnosis of BrS. The ECG returned to its baseline pattern eight hours after the initiation of the test, and no cardiovascular complications occurred. This case highlights the clinical utility and safety of oral propafenone as an effective alternative diagnostic challenge for unmasking BrS in resource-limited environments. Furthermore, it emphasizes the necessity of utilizing extended monitoring protocols due to the specific pharmacokinetic profile and delayed onset of action of oral agents.

Authors: Jaramillo Astudillo LF, Navas Moreira GA, Delgado Cedeño P, Tumbaco Mite CJ, Arteaga Herrera EC
Read the Original
Full article at Cureus
Open at Cureus →
The Valve Wire summarizes; we link out to primary sources for verification.
More in Aortic Valve (TAVR/TAVI)
Elsewhere in Today’s Issue